Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older who have been diagnosed with recurrent or metastatic ovarian cancer, endometrial cancer, or another solid tumour.
• People who have at least one measurable area of cancer that doctors can track using standard imaging guidelines (note: people whose only measurable areas of cancer are in the brain or bones are not eligible).
• People who are able to provide a tumour tissue sample — either from a new biopsy or, if a new biopsy is not possible, from stored tumour tissue collected within the past two years.
• People who are in good enough general health to be up and about for most of the day, with no significant decline in the two weeks before starting the trial (confirm with trial site).
• People with a life expectancy of at least 12 weeks.
• Women who could become pregnant must be willing to use effective contraception and avoid breastfeeding from the time of signing the consent form until six months after the last dose; men must agree to use condom-based contraception from signing consent until six months after the last dose.
• Women who could become pregnant must have a negative pregnancy test within seven days before the first dose.
• People who are willing to take part voluntarily, understand what the study involves, and are able to sign a consent form.

Who may not be able to join:

• People who have previously received or are currently receiving treatments that specifically target a protein called B7-H4.
• People who have received standard chemotherapy, other anti-cancer drugs, or experimental treatments within 14 days before the first dose.
• People who have received large-molecule anti-cancer treatments (such as monoclonal antibodies or immunotherapy) within 28 days before the first dose.
• People who have received radiation therapy to a localised area within 2 weeks before the first dose, or radiation covering a large area of the body or more than 30% of the bone marrow within 4 weeks before the first dose.
• People who have had major surgery (such as brain, chest, or abdominal surgery) within 4 weeks before the first dose.
• People currently taking certain medications that affect how the body processes drugs (specific enzyme inhibitors or inducers — confirm with trial site), or medications known to affect heart rhythm in a dangerous way.
• People who still have moderate or severe side effects from previous cancer treatment (hair loss and certain nerve-related effects are exceptions).
• People who have a build-up of fluid in the chest or abdomen that requires medical treatment.
• People with a known history of a previous or different cancer.
• People with cancer that has spread to the brain, unless it meets specific conditions: it is not causing symptoms, has been medically stable for at least four weeks, has not required steroid treatment for at least two weeks, has not been treated with brain radiation or surgery in the past four weeks, has no history of bleeding in the brain or spine, and there is at least one measurable area of cancer outside the brain.
• People with poor bone marrow function or reduced liver or kidney function (confirm with trial site for specific values).
• People with abnormal heart test results, serious or uncontrolled heart conditions, serious or poorly controlled diabetes, or serious or poorly controlled high blood pressure.
• People who have had significant bleeding within the past month, or serious blood clot events (arterial or venous) within the past three months.
• People who have had a serious infection within the past four weeks.
• People who have used long-term steroid treatment (30 days or more) within the past month, who need ongoing steroid treatment, or who have a condition affecting the immune system, or a history of organ transplant.
• People with active hepatitis B, hepatitis C, tuberculosis, syphilis, or HIV infection.
• People with serious liver conditions such as hepatic encephalopathy, hepatorenal syndrome, or significant cirrhosis.
• People with moderate or severe lung disease that could affect breathing or make it difficult to monitor for lung-related side effects.
• People with a history of severe neurological or psychiatric illness.
• Women who are pregnant, breastfeeding, or planning to become pregnant during the study.
• People who have received a live attenuated vaccine within four weeks before the first dose.
• People who have had a significant allergic or hypersensitivity reaction within four weeks before the first dose, or who have a history of severe allergic reactions (such as anaphylactic shock) or severe reactions to infusions, or who are known to be allergic to any ingredient in the study drug (HS-20089).
• People who, in the opinion of the trial investigators, are unlikely to follow the study requirements or have any condition that could affect their safety or the reliability of the study results.

Important: Always verify eligibility with the trial site directly before applying.